Seattle Genetics initiates Phase Ii trial of Adcetris for Hodgkin Lymphoma Seattle Genetics initiated a phase II clinical trial evaluating ADCETRIS (brentuximab vedotin) as a front-line therapy for patients age 60 or older with newly diagnosed Hodgkin lymphoma. The trial is designed to assess the efficacy and tolerability of ADCETRIS as a monotherapy for older HL patients who have received no prior treatment. The study is expected to enroll up to 20 patients at multiple centers in the United States.
News For SGEN From The Last 14 Days
Check below for free stories on SGEN the last two weeks.
Subscribe for More Information